ABSTRACT
Aims To investigate real-world treatment attrition, concomitant use of pharmaceuticals with known drug-interactions, total cost of care, claims-based outcomes, and health disparities for individuals initiated on esketamine therapy in the United States.
Methods Individuals aged 18-64 with >=1 adjudicated claim for esketamine intranasal spray from 2019 to 2022 in the Optum Labs Data Warehouse (OLDW) were included. Continuous health plan enrollment was required for 6 months prior and 6 months post-esketamine start date. Medical claims, pharmacy claims data, and socioeconomic data were descriptively analyzed to investigate characteristics of the real-world esketamine cohort.
Results There were 833 individuals in the esketamine analysis cohort. 33% had <8 treatment sessions and did not finish the first stage of treatment (induction phase). Use of pharmaceuticals with drug interactions was high-60.2% had at least one prescription fill for a drug with a known esketamine interaction in the 90-day window after esketamine initiation. Total costs of care went from $2,905 per patient per month (PPPM) in the baseline period to $5,734 PPPM in the follow-up period. Emergency department utilization with mental-health related diagnoses reduced by 42.5% in the follow-up period. PPPM utilization for office visits, excluding all claims on esketamine treatment days, went up 45% in the follow-up period. The esketamine cohort was pharmaceutically complex, and many of them had fractured care: 20% had prescription fills for >=11 drugs in the follow-up period. 18.6% percent of the cohort had >=7 drug-prescribing providers, and over 35% of the cohort had encounters with more than 10 healthcare practitioners in the follow-up period. The esketamine cohort had 26.6% more individuals in the highest socioeconomic status quintile (least socially deprived), compared to individuals with treatment-resistant depression (TRD), not initiated on esketamine.
Limitations This was a retrospective cohort descriptive analysis with small sample sizes. Additional statistical analysis was not performed.
Conclusions The esketamine cohort was characterized by considerable complexity from both a polypharmacy and lifestyle perspective. These contextual factors likely had significant bearing on adoption, access, and eventual claims-based outcomes. Understanding the interplay of these factors with the treatment dynamics of consciousness-altering compounds will be important to obtain the best real-world results from therapeutic classes with psychedelic compounds.
Competing Interest Statement
BT conceived of the research idea and analysis while a graduate student at University of St. Thomas and was also an employee at UnitedHealth Group and held stock in the company.
Funding Statement
No funding was received for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of UnitedHealth Group Office of Human Research Affairs waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data is not publicly available due to data use agreement.
